Radient Pharmaceuticals Corp (RPC), a US based in-vitro diagnostic (IVD) company, through its subsidiary AMDL Diagnostics, has entered into an exclusive 5-year full-service distribution agreement with Phu Gia Trading to expand Onko-Sure IVD cancer test into the Vietnam, Laos and Cambodia healthcare markets.
Onko-Sure is a simple, non-invasive, patent-pending and regulatory-approved in-vitro diagnostic test for the monitoring of colorectal cancer and for lung cancer detection and treatment monitoring by measuring the accumulation of Fibrin and Fibrinogen Degradation Products (FDP) in the blood.
Under the agreement, Phu Gia has committed to purchase a minimum of 2,425 Onko-Sure kits over the duration of the agreement and the company will represent RPC while obtaining regulatory clearances and providing marketing, sales, and distribution services for Onko-Sure in diagnostic centers and clinical labs throughout the designated territory.
Phu Gia president Jack Nguyen said that their full-service distribution partnership with Radient allows them to work closely with top diagnostic centers and clinical labs in Vietnam, and reach healthcare professionals across the designated territories of Vietnam, Cambodia and Laos.